Hypertension - Pipeline Review, H1 2012

Global Markets Direct, February 2012, Pages: 205

Hypertension – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Hypertension - Pipeline Review, H1 2012', provides an overview of the Hypertension therapeutic pipeline. This report provides information on the therapeutic development for Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypertension. 'Hypertension - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hypertension.
- A review of the Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hypertension pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Hypertension.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Hypertension therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Hypertension Therapeutic Products under Development, Key Players in Hypertension Therapeutics, Hypertension Pipeline Overview, Hypertension Pipeline, Hypertension Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hypertension Overview
Therapeutics Development
An Overview of Pipeline Products for Hypertension
Hypertension Therapeutics under Development by Companies
Hypertension Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Hypertension Therapeutics – Products under Development by Companies
Hypertension Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Hypertension Therapeutics Development
Shionogi & Co., Ltd.
Sanofi-Aventis
Eli Lilly and Company
Daiichi Sankyo Company, Ltd
Merck & Co., Inc.
Dainippon Sumitomo Pharma Co., Ltd.
Takeda Pharmaceutical Company Limited
Novartis AG
Samyang Corporation
Actelion Ltd
Axcan Pharma Inc.
Chong Kun Dang Pharmaceutical
Dong-A Pharmaceutical Co., Ltd.
Forest Laboratories, Inc.
Mitsubishi Tanabe Pharma Corporation
Recordati S.p.A.
Sigma-Tau S.p.A.
IntelGenx Technologies Corp.
Medivir AB
Compugen Ltd.
Palatin Technologies, Inc.
BTG International Ltd
Cytokinetics, Inc
Yuhan Corporation
Torrent Pharmaceuticals Limited
Choongwae Pharma Corp
Hanall Pharmaceutical Co., Ltd.
Cytos Biotechnology AG
Ahn-Gook Pharmaceutical Co., Ltd.
LG Life Sciences, Ltd
SCOLR Pharma, Inc.
DiaMedica Inc.
AFFiRiS AG
Respiratorius AB
Arete Therapeutics Inc.
Global Health Ventures Inc.
Circ Pharma Limited
QUANTUM GENOMICS Corp.
Intercept Pharmaceuticals, Inc.
Bial Group
Biolink Group AS
Pharnext SAS
Cellceutix Pharmaceuticals, Inc.
Aristo Pharmaceuticals Ltd.
MicroDose Therapeutx, Inc.
Vicore Pharma AB
Asklepion Pharmaceuticals, LLC.
Serodus AS
Hypertension – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Edarbi - Drug Profile
Angiotensin Therapeutic Vaccine - Drug Profile
DSP-8153 - Drug Profile
EUR 1000 - Drug Profile
LCZ696 - Drug Profile
PL-3994 - Drug Profile
CYT006-AngQb - Drug Profile
AR9281 - Drug Profile
Simvastatin + ACE Inhibitors - Drug Profile
Obeticholic acid - Drug Profile
Chlorthalidone + Amiloride - Drug Profile
Candesartan - Drug Profile
RHB-101 - Drug Profile
L-Arginine - Drug Profile
Melatonin_ - Drug Profile
Ramipril - Drug Profile
Sodium Nitroprusside - Drug Profile
Rostafuroxin - Drug Profile
Losartan + Hydrochlorothiazide - Drug Profile
Xenical - Drug Profile
Urapidil - Drug Profile
Carvedilol Phosphate + Lisinopril - Drug Profile
Benazepril + Valsartan - Drug Profile
Epigallocatechin Gallate - Drug Profile
Lisinopril - Drug Profile
Citrupress IV - Drug Profile
Rasilez + Ramipril - Drug Profile
Aprovel + Amlodipine - Drug Profile
Zydena - Drug Profile
Lovenox + Aspegic - Drug Profile
S-474474 - Drug Profile
Spironolactone - Drug Profile
Ventavis - Drug Profile
Octreolin - Drug Profile
Acetyl-L-Carnitine + Simvastatin - Drug Profile
Bevacizumab - Drug Profile
Olmesartan + Amlodipine - Drug Profile
Olmesartan + Azelnidipine - Drug Profile
Candesartan/Valsartan + Amlodipine - Drug Profile
Candesartan/Varsartan + Azelnidipine - Drug Profile
Propranolol + Norfloxacin + VSL#3 - Drug Profile
Losartan - Drug Profile
Spironolactone - Drug Profile
CKD-828 - Drug Profile
Lercanidipine + Valsartan - Drug Profile
Candesartan + Nifedipine + Metoprolol - Drug Profile
Lisinopril + Nifedipine + Metoprolol - Drug Profile
Aliskiren + Valsartan + Hydrochlorothiazide - Drug Profile
Carvedilol + Lisinopril - Drug Profile
Imidapril - Drug Profile
ACT-280778 - Drug Profile
Edarbyclor - Drug Profile
Telmisartan + Amlodipine + Hydrochlorothiazide - Drug Profile
Danshen + Gegen - Drug Profile
Cilnidipine - Drug Profile
Fosinopril - Drug Profile
Angipars - Drug Profile
Sodium Lactate - Drug Profile
6R-BH4 - Drug Profile
6R-BH4 - Drug Profile
Allopurinol - Drug Profile
Bisoprolol PM - Drug Profile
Probenecid - Drug Profile
Aliskiren + Losartan - Drug Profile
Allopurinol - Drug Profile
AHU377 + Valsartan - Drug Profile
Pterostilbene - Drug Profile
Atorvastatin - Drug Profile
Benazepril - Drug Profile
LFF269 - Drug Profile
AJH801 - Drug Profile
Lercanidipine + Enalapril - Drug Profile
Nebivolol + Valsartan - Drug Profile
Pitavastatin + Valsartan - Drug Profile
Menthol - Drug Profile
Hypertension Therapeutics – Drug Profile Updates
Hypertension Therapeutics – Discontinued Products
Hypertension Therapeutics - Dormant Products
Hypertension – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Hypertension, H1 2012
Products under Development for Hypertension – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Development by Companies, H1 2012 (Contd..2)
Number of Products under Development by Companies, H1 2012 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Shionogi & Co., Ltd., H1 2012
Sanofi-Aventis, H1 2012
Eli Lilly and Company, H1 2012
Daiichi Sankyo Company, Ltd, H1 2012
Merck & Co., Inc., H1 2012
Dainippon Sumitomo Pharma Co., Ltd., H1 2012
Takeda Pharmaceutical Company Limited, H1 2012
Novartis AG, H1 2012
Samyang Corporation, H1 2012
Actelion Ltd, H1 2012
Axcan Pharma Inc., H1 2012
Chong Kun Dang Pharmaceutical, H1 2012
Dong-A Pharmaceutical Co., Ltd., H1 2012
Forest Laboratories, Inc., H1 2012
Mitsubishi Tanabe Pharma Corporation, H1 2012
Recordati S.p.A., H1 2012
Sigma-Tau S.p.A., H1 2012
IntelGenx Technologies Corp., H1 2012
Medivir AB, H1 2012
Compugen Ltd., H1 2012
Palatin Technologies, Inc., H1 2012
BTG International Ltd, H1 2012
Cytokinetics, Inc, H1 2012
Yuhan Corporation, H1 2012
Torrent Pharmaceuticals Limited, H1 2012
Choongwae Pharma Corp, H1 2012
Hanall Pharmaceutical Co., Ltd., H1 2012
Cytos Biotechnology AG, H1 2012
Ahn-Gook Pharmaceutical Co., Ltd., H1 2012
LG Life Sciences, Ltd, H1 2012
SCOLR Pharma, Inc., H1 2012
DiaMedica Inc., H1 2012
AFFiRiS AG, H1 2012
Respiratorius AB, H1 2012
Arete Therapeutics Inc., H1 2012
Global Health Ventures Inc., H1 2012
Circ Pharma Limited, H1 2012
QUANTUM GENOMICS Corp., H1 2012
Intercept Pharmaceuticals, Inc., H1 2012
Bial Group, H1 2012
Biolink Group AS, H1 2012
Pharnext SAS, H1 2012
Cellceutix Pharmaceuticals, Inc., H1 2012
Aristo Pharmaceuticals Ltd., H1 2012
MicroDose Therapeutx, Inc., H1 2012
Vicore Pharma AB, H1 2012
Asklepion Pharmaceuticals, LLC., H1 2012
Serodus AS, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Hypertension Therapeutics – Drug Profile Updates
Hypertension Therapeutics – Discontinued Products
Hypertension Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Hypertension, H1 2012
Products under Development for Hypertension – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Renal Failure - Pipeline Review, H1 2013
• Eczema - Pipeline Review, H1 2013
• Liver Diseases - Pipeline Review, H1 2013
• Alzheimer's Disease – Pipeline Review, H1 2013
• Osteoporosis - Pipeline Review, H1 2013
• Obesity - Pipeline Review, H1 2013
• Hypertension - Pipeline Review, H2 2012
• Macular Degeneration - Pipeline Review, H1 2013
• Allergic Rhinitis - Pipeline Review, H1 2013
• Chemotherapy Effects – Pipeline Review, H1 2013